Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT

Medicine & Life Sciences

• Plasma Exchange 80%
• Vasculitis 67%
• Glucocorticoids 60%
• Chronic Kidney Failure 58%
• Cytoplasm 53%
• Neutrophils 51%
• Antibodies 36%
• Biomedical Technology Assessment 10%
• Health Services Research 9%
• National Institutes of Health (U.S.) 8%
• Confidence Intervals 7%
• Immunosuppressive Agents 6%
• Microscopic Polyangiitis 6%
• Myeloblastin 5%
• Infections 5%
• Biomarkers 5%
• Granulomatosis with Polyangiitis 5%
• Rituximab 4%
• Kidney 4%
• North America 4%
• New Zealand 4%
• Prednisolone 4%
• Mortality 4%
• Peroxidase 3%
• Glomerular Filtration Rate 3%
• Cyclophosphamide 3%
• Autoantibodies 3%
• Sample Size 3%
• Libraries 3%
• Autoimmune Diseases 3%
• Japan 3%
• Economics 3%
• Data Analysis 3%
• Meta-Analysis 3%
• Randomized Controlled Trials 2%
• Therapeutics 2%
• Hemorrhage 2%
• Physicians 2%
• Morbidity 2%
• Lung 2%
• Health 2%
• Incidence 2%

Social Sciences

• end stage renal disease 100%
• death 47%
• Group 19%
• technology assessment 19%
• confidence 18%
• mortality 13%
• Health Care Research 12%
• blood samples 11%
• health 11%
• Health Economics 10%
• cause 9%
• induction 8%
• morbidity 8%
• incidence 6%
• New Zealand 6%
• website 6%
• physician 6%
• Japan 6%
• time 5%
• funding 5%
• lack 4%
• trend 4%
• management 3%
• evidence 3%